Whether or not the only genetic (or epigenetic) hit, BCR-ABL1 is the main disease driver in CP CML, as testified by the remarkable clinical efficacy of TKIs. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.